The First in Human INCEPTR trial reported at the Joint Congress of the European Society for Paediatric Endocrinology and the European Society of Endocrinology in Denmark this week is one of three projects involving Novosorb BTM that Prof. Toby Coates has been working on.
This First in Human trial received $750,000 funding from TD1 Breakthrough Australia and TD1 Breakthrough International.
Another Coates project is Intracutaneous Ectopic Pancreas (IEP) creation by seeding Human Stem Cell-derived Islets (HSCI) into integrated BTM.
This project is said to be the result of a long standing collaboration between Novo Nordisk and Beta Cell Technologies. The aim of this project has been to determine the effectiveness of intracutaneous islet transplantation of stem cell derived islets. The stated broader aim is to negate the need for islets purified from deceased organ donors, leading to a more consistent supply and quality of islets for transplantation. In addition, by removing the need for donor islets the transplantation procedure can be planned for in advance, with the islets provided at the optimal time for transplantation. Leading to better outcomes for transplant recipients.
Between 2019 and 2020, this project received $1,254,357 funding from a “Commercial Corporation” and between 2020 and 2023, $500,000 funding was said to be “Commercial in Confidence (International)”. *
A further project has been Adrenal cell transplantation for Addison’s disease using biodegradable temporising matrix technology. In this project, a pilot study was conducted of autologous adrenocortical cell transplantation into a cutaneous site using integrated BTM in a porcine model.
The transplanted cells showed a capability to survive and proliferate within the BTM site and an ability to self-organize into discrete tissue organoids. However, clinically relevant systemic hormone production wasn’t achieved, with the researchers suggesting that the insufficient function was likely attributable to insufficient cells being delivered.
* 2019 and 2023 Annual Research Reports, Central Northern Adelaide Renal and Transplantation Service (CNARTS)
PNV Price at posting:
$1.49 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)